Product Sales (Tables)

9 Months Ended

Sep. 30, 2018

Net product sales consist of the following:



	Three Months Ended September 30,				Nine Months Ended September 30,
Net Product Sales in the United States	2018		2017		2018		2017
EYLEA^®	$	1,021,782	$	953,279	$	2,997,829	$	2,727,132
ARCALYST^®	3,706		4,088		11,950		12,613
	$	1,025,488	$	957,367	$	3,009,779	$	2,739,745

The collaboration revenue we earned from Sanofi is detailed below:



	Three Months Ended September 30,						Nine Months Ended September 30,
Sanofi Collaboration Revenue	2018			2017			2018			2017
Antibody:
Reimbursement of Regeneron research and development expenses	$	76,150		$	128,539		$	201,026		$	421,056
Reimbursement of Regeneron commercialization-related expenses	103,666			90,339			292,756			251,002
Regeneron's share of losses in connection with commercialization of antibodies	(38,924		)	(98,315		)	(182,595		)	(328,998		)
Other	33,166			41,848			82,150			84,338
Total Antibody	174,058			162,411			393,337			427,398
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	74,797			61,649			225,675			188,408
Reimbursement of Regeneron commercialization-related expenses	3,236			1,115			6,507			1,864
Other	4,174			20,000			57,989			60,000
Total Immuno-oncology	82,207			82,764			290,171			250,272
	$	256,265		$	245,175		$	683,508		$	677,670

Revenue earned in connection with our Bayer EYLEA collaboration is as follows (note that the table excludes amounts in connection with our Bayer Ang2 antibody and PDGFR-beta antibody collaboration agreements, which are described below):



	Three Months Ended September 30,				Nine Months Ended September 30,
Bayer EYLEA Collaboration Revenue	2018		2017		2018		2017
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	243,152	$	205,367	$	721,522	$	571,126
Reimbursement of Regeneron EYLEA development expenses	1,676		6,053		8,811		10,833
Other	20,764		15,714		45,321		36,910
	$	265,592	$	227,134	$	775,654	$	618,869

Schedules of Concentration of Risk, by Risk Factor

The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the three and nine months ended September 30, 2018 and 2017. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Besse Medical, a subsidiary of AmerisourceBergen Corporation	57	%	51	%	56	%	51	%
McKesson Corporation	36	%	29	%	37	%	29	%
Curascript SD Specialty Distribution, a subsidiary of Express Scripts	**		19	%	**		19	%
** Sales to Curascript SD Specialty Distribution represented less than 10% of total gross product revenue during the period.

Sales Related Deductions Activity

The following table summarizes the provisions, and credits/payments, for these sales-related deductions during the nine months ended September 30, 2018 and 2017.



	Rebates, Chargebacks, and Discounts			Distribution- Related Fees			Other Sales- Related Deductions			Total
Balance as of December 31, 2017	$	29,840		$	34,142		$	21,320		$	85,302
Provisions	159,060			155,523			29,730			344,313
Credits/payments	(145,813		)	(150,956		)	(35,756		)	(332,525		)
Balance as of September 30, 2018	$	43,087		$	38,709		$	15,294		$	97,090

Balance as of December 31, 2016	$	12,712		$	29,465		$	3,674		$	45,851
Provisions	121,599			140,860			33,518			295,977
Credits/payments	(108,811		)	(136,272		)	(21,444		)	(266,527		)
Balance as of September 30, 2017	$	25,500		$	34,053		$	15,748		$	75,301